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Background: Rituximab is effective for SLE in open label series however level of clinical response varies and was not
superior to standard of care in randomised trials.  We previously showed that clinical response was associated with the
depth of initial B cell depletion and relapse was associated with early plasmablast repopulation[1].
Objectives: To validate B cell depletion as a predictor of response to rituximab in SLE as a basis to develop more
effective B cell targeted therapy.
Methods: The published discovery cohort included 38 renal and extra-renal lupus patients.  A validation cohort of 46 new
patients was recruited.  All patients received an initial cycle of 2 infusions of 1000mg rituximab, each preceded by 100mg
methylprednisolone.  Rituximab was repeated on clinical relapse.  Concomitant therapy with cyclophosphamide was not
used. Oral immunosuppressants were continued if used at baseline.  Oral prednisolone doses varied. B cell depletion
using a protocol optimized to detect low numbers of B cell subsets and plasmablasts was measured at baseline, after
both infusions of rituximab (6 weeks) and at early B cell repopulation (6 months).  Complete depletion was defined as
total B cell count <0.0001 x 109/L
Results: Depletion and response data were available for 84/100 patients.  Overall complete depletion rate was 54%.
Cohort Depletion Non Response Response p
Discovery (n=38) Incomplete 7/22 (32%) 15/22 (68%) 0.012
Complete 0/16 (0%) 16/16 (100%)
Validation (n=46) Incomplete 6/17 (35%) 11/17 (65%) 0.014
Complete 2/29 (7%) 27/29 (93%)
Combined (n=84) Incomplete 13/39 (33%) 26/39 (67%) 0.001
Complete 2/45 (4%) 43/45 (96%)
Incomplete depletion was predicted at baseline by low complement C4 (p=0.044) but not baseline BILAG score or
immunosuppressant use.  In original cohort there was a significant association between plasmablast repopulation
(>0.0008x109/L) and time to relapse < 18 months (p=0.024).  Follow up for relapse was limited to 22/36 responders in the
validation cohort at the time of analysis, with a trend to the same association (p=0.119).
Conclusions: We have validated depth of B cell depletion as a predictor of response to rituximab in SLE.  Clinical trials
using more intensive rituximab treatment regimens, or alternative CD20 molecules are likely to increase clinical response
rates to B cell depletion in clinical trials.  B cell subsets should be monitored in the routine care of SLE patients receiving
rituximab and repeat infusions considered if early depletion is incomplete or plasmablast repopulation is detected at 6
months.
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